Skip to main content

Table 13 Studies reporting measures of quality of life

From: The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review

Study

Measure

Control Group

Intervention Group

Statistical Test or Model

p-value

Estimate of Effect

Direction of Effect

Overall Effect Direction

(S16) Javakhishvili et al., 2021 [84]

WHOQOL-BREF score, Physical Domain (0 = low, 100 = high)

Mean 58.95 (SD 14.82)a

Mean 57.24 (SD 16.22)b

NR

 > 0.05

NR

Favours control

Negative

WHOQOL-BREF score, Psychological Domain (0 = low, 100 = high)

Mean 59.11 (SD 10.12)a

Mean 57.04 (SD 10.73)b

NR

 < 0.05

NR

Favours control

WHOQOL-BREF score, Social Domain (0 = low, 100 = high)

Mean 68.93 (SD 14.51)a

Mean 67.12 (SD 16.02)b

NR

 > 0.05

NR

Favours control

WHOQOL-BREF score, Environmental Domain (0 = low, 100 = high)

Mean 53.51 (SD 11.9)b

Mean 52.5 (SD 12.39)b

NR

 > 0.05

NR

Favours control

(S22) Lintzeris et al., 2022 [90]

Australian Treatment Outcome Profile’s quality of life scale score (1 = low, 10 = high)

Mean 6.7 (SD 1.8)c

Mean 6.8 (SD 1.6)d

Paired t-test

0.157

NR

Favours intervention

Positive

  1. aControl group: OAT clients who attended the OST site for medication every day during the pandemic
  2. bIntervention group: OAT clients receiving take-home doses during pandemic
  3. cControl group: OAT clients pre-pandemic
  4. dIntervention group: OAT clients post-pandemic